The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation
Key facts
- Who runs it
- Centro Cardiologico Monzino
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 260 people enrolled
- Started
- 1 Dec 2025
- Expected to end
- 1 Dec 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- mitral valve surgery
- Clinical Follow up
- Record updated
- 10 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- age ≥ 18 years
- patients agree to all provisions of the protocol
- patient can give informed consent
- TTE diagnosis of MVP (defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the MV annulus in long-axis views), and chronic severe MR
- no symptoms
- LVEF > 60%, LVESD < 40 mm and LVESDi < 20 mm/m2
- sinus rhythm
- PASP value at rest < 50 mmHg
- LA volume index ≥ 60 mL/m2 or diameter ≥ 55 mm or normal LA size if likelihood of a successful and durable repair without residual MR is >95% and expected mortality rate is <1%
- ongoing adequate treatment per applicable standards
- patient referred for isolated MV repair or replacement
- willingness to undergo TTE, CMR and CPET at different timepoints
Who cannot take part
- planned concomitant cardiac surgical procedures (e.g. other valve procedures, or coronary artery bypass)
- coexistence of other cardiomyopathies or other > mild valve diseases
- untreated clinically significant coronary artery disease requiring revascularization
- need for an emergent/urgent surgery for any reason or any planned cardiac surgery within the next months
- hemodynamic instability requiring inotropic support or mechanical heart assistance
- sustained cardiac arrhythmias
- like expectancy < 12 months due to non-cardiac conditions
- inability to provide informed consent
- pregnancy or planned pregnancy within next 2 years
- poor TTE image quality
- usual contraindications to CMR and/or to gadolinium administration
- inability to sustain a breath hold
- known intracardiac shunts
- active endocarditis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Mitral regurgitation (MR) is the second most frequent valvular heart disease and the second most frequent indication for valve surgery in Europe.
Read full original descriptionShow less
The management of patients with MV prolapse (MVP) and severe MR is mainly guided by symptoms, left ventricular (LV) dimensions and ejection fraction (EF), pulmonary artery systolic pressure (PASP) and atrial fibrillation (AF) occurrence.
According to the ESC/EACTS guidelines, surgical treatment of severe primary MR is indicated (recommendation Class I, Level B) in case of:
* symptomatic patients considered operable by the Heart Team; * asymptomatic patients with LV dysfunction, intended as a LVEF ≤ 60% and/or LV end-systolic diameter (LVESD) ≥ 40 mm or LVESD indexed for body mass area (LVESDi) ≥ 20 mm/m2; * low-risk asymptomatic patients without LV dysfunction (LVEF > 60%, LVESD < 40 mm, LVESDi < 20 mm/m2) when a durable result is likely, if at least 3 of the following criteria are fulfilled:
* AF secondary to MR; * PASP value at rest > 50 mmHg; * significant left atrium (LA) dilation, intended as LA volume index ≥ 60 mL/m2 or diameter ≥ 55 mm * concomitant secondary tricuspid regurgitation ≥ moderate.
Surgery should be considered (recommendation Class IIa, Level B) in asymptomatic patients with preserved LV function (LVEF > 60%, LVESD < 40 mm, LVESDi < 20 mm/m2), when one of the following findings is present1:
* AF secondary to MR; * PASP value at rest > 50 mmHg; * LA volume index ≥ 60 mL/m2 or diameter ≥ 55 mm, provided surgical risk is low, surgery is performed in a Heart Valve Center and a durable MV repair is likely.
Preliminary data suggest that in patients with MVP, especially with Barlow's disease phenotype, left-sided chambers' enlargement and functional impairment may be disproportionate related to MR grade. Indeed, patients with BD and ≤ mild-to-moderate MR show larger LA and LV dimensions as compared to controls matched for age, gender and cardiovascular risk factors. These findings challenge the assumption that LA and LV remodeling is a direct effect of volume overload, with possible implications regarding the indication for MV intervention.
On the other hand, low mortality and good durability of valve repair has led some experienced centers to perform also early surgery, namely in any asymptomatic patient with severe MR, normal LV size and function, regular sinus rhythm, normal PASP and normal LA size, as long as surgical risk is very low and likelihood of successful valve repair is high. However, some studies have demonstrated that asymptomatic patients with severe degenerative MR can be safely followed up in experienced hands and remain free of indications for surgery for extensive periods of time. A watchful waiting strategy resulted in timely referral to surgery, excellent long-term survival, and good surgical outcomes, though requiring careful and active surveillance. Several authors agree that prospective randomized trials comparing active surveillance and early elective surgery are needed. There are also data suggesting that MR quantification by CMR has better discriminative power in identifying asymptomatic patients with degenerative MR and adverse outcomes as compared to the echocardiographic-derived integrative approach. Further prospective studies are necessary to validate these preliminary findings.
The 4 groups in the trial
- Blinded CMR - Group C1Existing treatment, for comparison
Patients undergoing sugery based on TTE, showing less than severe MR by CMR
Treatment: mitral valve surgery
- Unblinded CMR - Group AOther group
Patients with severe MR, as assessed by TTE, with less than severe MR documented by CMR (Group A), undergo clinical follow-up.
Treatment: Clinical Follow up
- Unblinded CMR - Group BExisting treatment, for comparison
Patients with severe MR, as quantified by both TTE and CMR, undergo surgery.
Treatment: mitral valve surgery
- Blinded CMR - Group C2Existing treatment, for comparison
Patients undergoing surgery based on TTE, showing severe MR by CMR
Treatment: mitral valve surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation (the INTEGRATE Study)
- Record updated
- 10 June 2026